Table III.
Association between GAS5 expression levels and clinicopathological features in the CRC patients (N=75).
| GAS5 | ||||
|---|---|---|---|---|
| Characteristics | n | Low (n=37) | High (n=38) | P-value |
| Age (years) | 0.786 | |||
| <60 | 35 | 18 | 17 | |
| ≥60 | 40 | 19 | 21 | |
| Sex | 0.125 | |||
| Male | 35 | 17 | 18 | |
| Female | 40 | 20 | 20 | |
| Tumor size (cm) | 0.062 | |||
| <5 | 44 | 26 | 18 | |
| ≥5 | 31 | 11 | 20 | |
| Differentiation | 0.170 | |||
| Well/moderate | 29 | 3 | 26 | |
| Poor | 46 | 34 | 12 | |
| Lymphatic node metastasis | 0.016 | |||
| Present | 36 | 33 | 3 | |
| Absent | 39 | 4 | 35 | |
| Clinical stages | 0.022 | |||
| I/II | 38 | 3 | 35 | |
| III/IV | 37 | 34 | 3 | |
| CA19-9 level (U/ml) | 0.690 | |||
| <37 | 38 | 19 | 19 | |
| ≥37 | 37 | 18 | 19 | |
| CEA level (ng/ml) | 0.081 | |||
| <5 | 23 | 3 | 20 | |
| ≥5 | 52 | 34 | 18 | |
The median value of GAS5 expression levels in CRC patients is 0.8699. P<0.05 indicates a statistically significant difference. CRC, colorectal cancer; GAS5, growth arrest specific 5; CA19-9, cancer antigen 19-9; CEA, carcinoembryonic antigen. Significant P-values are displayed in bold print.